Vaccine

Ascend Completes GMP Certification for Quality Control Testing in Munich FacilityAscend Completes GMP Certification for Quality Control Testing in Munich Facility

Ascend Completes GMP Certification for Quality Control Testing in Munich Facility

- Enables streamlined stability testing and release of higher quality AAV-based gene therapy products. - Provides much needed European capacity…

2 months ago
Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of DirectorsMaravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science…

2 months ago
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug DevelopmentOPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development

OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development

Will provide expertise across ModeX’s portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer…

2 months ago
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of ColorDupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall…

2 months ago
Advanced Biological Research Group to Study Effects of mRNA on Women’s ReproductionAdvanced Biological Research Group to Study Effects of mRNA on Women’s Reproduction

Advanced Biological Research Group to Study Effects of mRNA on Women’s Reproduction

JACKSONVILLE, Fla., June 5, 2025 /PRNewswire/ -- Advanced Biological Research Group (ABRG), a 501c3, has announced its second study to…

2 months ago
Elanco Releases New Report Highlighting the Significance of America’s Itchy Dogs and the Need for Itch ReliefElanco Releases New Report Highlighting the Significance of America’s Itchy Dogs and the Need for Itch Relief

Elanco Releases New Report Highlighting the Significance of America’s Itchy Dogs and the Need for Itch Relief

The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data…

2 months ago
DIOSynVax Presents Its Technology at the Invitation-Only Next Venture Capital Unit (VCU) Health Tech Showcase at the London Stock ExchangeDIOSynVax Presents Its Technology at the Invitation-Only Next Venture Capital Unit (VCU) Health Tech Showcase at the London Stock Exchange

DIOSynVax Presents Its Technology at the Invitation-Only Next Venture Capital Unit (VCU) Health Tech Showcase at the London Stock Exchange

CAMBRIDGE, United Kingdom and SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- DIOSynVax, a clinical-stage biotechnology company at the forefront…

2 months ago
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesotheliomaOncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma

Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma

Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma Paris,…

2 months ago
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal HealthConduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in…

2 months ago
Elicio Therapeutics Secures $10 Million in FinancingElicio Therapeutics Secures $10 Million in Financing

Elicio Therapeutics Secures $10 Million in Financing

Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June…

2 months ago